Clinical study on Biyuan Tongqiao Granules combined with tranilast in treatment of allergic rhinitis
Objective To explore the clinical effect of Biyuan Tongqiao Granules combined with tranilast in treatment of allergic rhinitis.Methods A total of 150 patients with allergic rhinitis treated in Qingdao Chengyang People's Hospital from August 2021 to May 2023 were selected and divided into control group(75 cases)and treatment group(75 cases)according to random number table method.Patients in the control group were po administered with Tranilast Capsules,1 grains/time,three times daily.Patients in the treatment group were po administered with Biyuan Tongqiao Granules on the basis of the control group,1 bag/time,three times daily.Patients in two groups were treated for 8 weeks.After treatment,the clinical evaluation was evaluated,the time of symptom relief,serological AQP5,IL-4,TNF-α and ICAM-1 levels,and the scores of RQLQ in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group was 97.33% ,which was significantly higher than that of the control group(86.67% ,P<0.05).After treatment,the symptoms relief time of nasal congestion,sneezing,nasal itching and runny nose in the treatment group were improved earlier than those in the control group(P<0.05).After treatment,the serum levels of AQP5,IL-4,TNF-α and ICAM-1 in two groups significantly decreased(P<0.05),and the levels of these serum factors in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,the RQLQ score of the two groups was significantly decreased(P<0.05),and which in the treatment group was significantly lower than that of the control group(P<0.05).Conclusion Biyuan Tongqiao Granules combined with tranilast can significantly improve the symptoms of allergic rhinitis,promote the weakening of organic inflammatory response,and improve the life quality of patients.
NETL
NSTL
万方数据
维普
